ESC 2024: Beta blocker treatment paradigm shifts for myocardial infarction
A shift in the beta-blocker treatment paradigm has arrived with the changing myocardial infarction treatment landscape, said a researcher at…
A shift in the beta-blocker treatment paradigm has arrived with the changing myocardial infarction treatment landscape, said a researcher at…
A shift in the beta-blocker treatment paradigm has arrived with the changing myocardial infarction treatment landscape, said a researcher at…
“Change begins now,” said the UK’s new prime minister, Sir Keir Starmer, in his 5 July victory speech. Ending the…
Whilst Prime Minister Rishi Sunak and Labour party leader Keir Starmer, centre attention on migration and tax policies, the UK…
As a 4 July UK general election looms on the horizon, experts say that the UK clinical trial landscape could…
Altimmune has taken another step to claim its share in the growing obesity drug market with new data showing its…
The Asia Pacific (APAC) region is leading the charge for adoptive cell therapy studies, says Scotty Chung-Siu, a managing analyst…
Lord James O’Shaughnessy, the former health minister, says real-time data sharing on commercial clinical activity in the UK will majorly…
Dr. Yooni Kim, the vice president of clinical services at Novotech, says Australia and South Korea are emerging as bubbling…
Following a 2023 review of the UK clinical trial landscape, Lord James O’Shaughnessy, the former health minister highlighted major change…